Clinical Significance of Measuring Levels of CEA, CA19-9 in Peritoneal Washing Fluid in Patients with Gastric Cancer.
10.5230/jkgca.2006.6.3.125
- Author:
Gyu Beom SHIM
1
;
Ji Hun PARK
;
Tea Young KOO
;
Hyun Sik MIN
Author Information
1. Department of Surgery, Konyang University College of Medicine, Daejeon, Korea. hsmin50@kyuh.co.kr
- Publication Type:Original Article
- Keywords:
Gastric cancer;
Peritoneal washing fluid;
CEA;
CA19-9
- MeSH:
Gastrectomy;
Humans;
Immunoassay;
Neoplasm Metastasis;
Polymerase Chain Reaction;
Prognosis;
Recurrence;
Reverse Transcription;
Serous Membrane;
Stomach Neoplasms*
- From:Journal of the Korean Gastric Cancer Association
2006;6(3):125-131
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Free cancer cells exfoliated from cancer-invaded serosa contribute to peritoneal dissemination, the most frequent pattern of recurrence in patients with gastric cancer. To detect free cancer cells, CEA and CA19-9 were introduced as the markers of gastric cancer, and many methods, such as cytology, immunoassay, and reverse transcription polymerase chain reaction (RT-PCR), exist for detecting them. The aim of this study is to define the clinical significance of using immunoassay to measure the levels of CEA and CA19-9 in the peritoneal washings in patients with gastric cancer. MATERIALS AND METHODS: The peritoneal washing fluids were obtained from 130 patients with gastric cancer who received a curative gastrectomy, palliative gastrectomy or open and closure. The pCEA and pCA19-9 levels were measured by using immunoassay and cytology. The results were compared with the clinicopathological data. RESULTS: The pCEA and pCA19-9 levels were correlated with tumor invasion, lymph-node metastasis, and stage (P<0.05). CONCLUSION: A correlation was found between elevated pCEA and pCA19-9 levels measured by immunoassay and the TNM stage. Therefore, a combined pCEA and pCA19-9 assay could be a sensitive detector of peritoneal dissemination, as well as a predictor of postoperative prognosis. pCEA and pCA19-9 may also determine the adjuvant management strategy.
